Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of investors including electronics giant Samsung.The funding will be used to support the commercial rollout of Element’s benchtop instrument for next-generation sequencing (NGS), Aviti, which is a competitor to Illumina technology like its mid-range NextSeq 2000 sequencer, and the forthcoming launch of Aviti24 that combines sequencing and cell characteristic mapping in a single device.Illumina is estimated to have around 80% of the global DNA sequencing market, with Element one of a new generation of rivals alongside the likes of PacBio and Singular Genomics, which launched their Onso and G4 instruments in 2022 and 2021, respectively.Element’s Series D takes the total amount raised by the company to date to around $680 million, coming after a similarly impressive $276 million third round in mid-2021.

Element Biosciences争取在由Illumina主导的DNA测序技术市场中分得一杯羹，这得益于一轮令人印象深刻的2.77亿美元融资，该融资得到了包括电子巨头三星（Samsung）在内的众多投资者的支持。这笔资金将用于支持Element用于下一代测序（NGS）的台式仪器Aviti的商业推出，Aviti是Illumina技术的竞争对手，如其中程NextSeq 2000测序仪，以及即将推出的Aviti24，它将测序和细胞特征映射结合在一个设备中。据估计，Illumina在全球DNA测序市场上占有约80%的份额，Element one是新一代竞争对手之一，与PacBio和Singular Genomics等公司一起，PacBio和Singular Genomics分别于2022年和2021年推出了Onso和G4仪器。Element的D系列将该公司迄今为止筹集的总金额提高到约6.8亿美元，而在2021年年中的第三轮筹集到了2.76亿美元。

The company was formed in 2017 with a backbone of ex-Illumina figures but operated pretty much under the radar until making a splash with the launch of Aviti in 2022.The company says its instruments offer a combination of high data quality, lower equipment and running costs, and improved flexibility over competitors.Analysts meanwhile have suggested that the next couple of years will be critical as the new entrants try to eat into Illumina’s market share.

该公司成立于2017年，拥有前Illumina公司的骨干，但在2022年推出Aviti之前，该公司几乎一直在秘密运作。该公司表示，其仪器集高数据质量、较低的设备和运行成本以及较竞争对手更大的灵活性于一身。与此同时，分析师表示，未来几年将是至关重要的，因为新进入者试图蚕食Illumina的市场份额。

However, they will do so at a time when the NGS market is growing at a phenomenal lick – with one analysis projecting it will more than triple from a value of around $8 billion in 2023 to over $31 billion in 2030.Element said in its statement on the financing that 190 Aviti instruments are now installed at customers’ labs, up from 40 just .

然而，他们将在NGS市场以惊人的速度增长的时候这样做，一项分析预测，NGS市场的价值将从2023年的80亿美元左右增加到2030年的310亿美元以上，增长超过三倍。Element在其融资声明中表示，目前在客户实验室安装了190台Aviti仪器，而目前只有40台。